Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Market volatility amid the ongoing earnings season and Middle East tensions continues to impact investor sentiment. In an uncertain backdrop, inves...

Best ETFs to Invest In, According to AI Analyst, 7/23/2026

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nek...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

Shares in medical group Johnson & Johnson ($JNJ) were healthier today after it received the green light to begin the “next era” of robotic surgery....

Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon

The approval opens a new market for the healthcare company. 


Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

Investors looking for steady cash payments can bank on NextEra ($NEE), Coca-Cola ($KO), and Johnson & Johnson ($JNJ). Top analysts covering these s...

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Steady Cash Flow, 7/21/26

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 10x Genomics (TXG), Elevance Health (ELV) and John...

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (TXG), Elevance Health (ELV) and Johnson & Johnson (JNJ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Johnson & Johnson (JNJ) and Glaukos (GKOS) with bull...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Johnson & Johnson, with a price target of $305.00. According to ...

Scotiabank Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Royalty Pharma (RPRX) and Johnson & Johnson (JNJ) wi...

Analysts Are Bullish on These Healthcare Stocks: Royalty Pharma (RPRX), Johnson & Johnson (JNJ)

On Wednesday, July 15, United Airlines ($UAL), Johnson & Johnson ($JNJ), and Morgan Stanley ($MS) will report their earnings. Johnson & Johnson and...

Polymarket Odds: Will UAL, JNJ, MS Beat Earnings Tomorrow?

This article highlights three ETFs rated Outperform (Buy) by TipRanks’ AI analyst. Exchange-traded funds (ETFs) help investors gain exposure to opp...

3 ETFs AI Analyst Says Are Worth Buying — July 14, 2026

Healthcare products group Johnson & Johnson ($JNJ) reports Q2 earnings this week – July 15. Its shares are up 25% in the year-to-date, helped by de...

Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.

Johnson & Johnson ($JNJ) is scheduled to report its fiscal second-quarter results before the market opens on July 15. JNJ stock is a “Dividend King...

Is Dividend King Johnson & Johnson (JNJ) a Buy Ahead of Earnings?

Stocks ended the week higher as continued enthusiasm for AI and technology shares helped lift the major U.S. indexes. The Dow Jones Industrial Aver...

The Week That Was, The Week Ahead: Macro and Markets, July 12

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNY) and Johnson & Johnson (JNJ). Sanofi (...

Analysts Conflicted on These Healthcare Names: Sanofi (SNY) and Johnson & Johnson (JNJ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nurix Therapeutics (NRIX) and Johnson & Johnson (JNJ...

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ)

Johnson & Johnson ($JNJ), Chevron ($CVX), and Cintas ($CTAS) are three Dividend Aristocrat stocks with a Strong Buy rating on Wall Street, accordin...

3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026

Exchange-traded funds (ETFs) provide an attractive investment option to gain exposure to stocks, bonds, sectors, commodities, and global markets. T...

Best ETFs to Invest In, According to AI Analyst, 7/8/2026

Citi analyst Joanne Wuensch reiterated a Buy rating on Johnson & Johnson on July 6 and set a price target of $298.00. The company’s shares closed y...

Johnson & Johnson (JNJ) Receives a Buy from Citi

Jim Cramer listed five stocks worth buying and all of them have rallied following his comments.


Jim Cramer Says Five Stocks Are In a ‘Great Place to Do Some Buying’

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX). John...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Johnson & Johnson (J...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Johnson & Johnson (JNJ)

Exchange-traded funds (ETFs) have become one of the most popular investment options, offering diversification, the flexibility to trade like stocks...

Best ETFs to Invest In, According to AI Analyst, 7/1/2026

Stocks ended the week lower as investors pulled back from risk assets and rotated into safer parts of the market. The Dow Jones Industrial Average ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$263.40	+1.59%	6.35M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$263.40	+1.6%	6.35M
3
4
5
6

JNJ

JNJ

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel